Abstract
Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significant scientific progress. The pathways to their commercial success, however, are poorly understood. In contrast to recent calls for a return to vertical integration, we suggest that relying on strong and unique horizontal relationships among biomedical organizations is more likely to shape technology convergence and increase success rates in achieving a tipping point or critical mass to address unmet medical needs, build new intellectual property and extend profitable growth from served markets.
| Original language | English |
|---|---|
| Pages (from-to) | 224-238 |
| Number of pages | 15 |
| Journal | Journal of Commercial Biotechnology |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biotechnology
- Management of Technology and Innovation
- Economics and Econometrics
Cite this
Pathways to biomedical tipping points : Vertical, horizontal or other. / Ahn, Mark J.; York, Anne S.; Rizova, Polly.
In: Journal of Commercial Biotechnology, Vol. 16, No. 3, 07.2010, p. 224-238.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pathways to biomedical tipping points
T2 - Vertical, horizontal or other
AU - Ahn, Mark J.
AU - York, Anne S.
AU - Rizova, Polly
PY - 2010/7
Y1 - 2010/7
N2 - Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significant scientific progress. The pathways to their commercial success, however, are poorly understood. In contrast to recent calls for a return to vertical integration, we suggest that relying on strong and unique horizontal relationships among biomedical organizations is more likely to shape technology convergence and increase success rates in achieving a tipping point or critical mass to address unmet medical needs, build new intellectual property and extend profitable growth from served markets.
AB - Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significant scientific progress. The pathways to their commercial success, however, are poorly understood. In contrast to recent calls for a return to vertical integration, we suggest that relying on strong and unique horizontal relationships among biomedical organizations is more likely to shape technology convergence and increase success rates in achieving a tipping point or critical mass to address unmet medical needs, build new intellectual property and extend profitable growth from served markets.
UR - http://www.scopus.com/inward/record.url?scp=77954117339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954117339&partnerID=8YFLogxK
U2 - 10.1057/jcb.2010.4
DO - 10.1057/jcb.2010.4
M3 - Review article
VL - 16
SP - 224
EP - 238
JO - Journal of Commercial Biotechnology
JF - Journal of Commercial Biotechnology
SN - 1462-8732
IS - 3
ER -